Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large decrease in short interest during the month of June. As of June 30th, there was short interest totaling 7,766 shares, a decrease of 99.0% from the June 15th total of 802,784 shares. Based on an average daily volume of 285,814 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Provectus Biopharmaceuticals Trading Down 1.7%

Provectus Biopharmaceuticals stock traded down $0.00 during midday trading on Friday, hitting $0.07. 63,360 shares of the company’s stock were exchanged, compared to its average volume of 159,340. Provectus Biopharmaceuticals has a 12-month low of $0.04 and a 12-month high of $0.10. The firm’s 50 day simple moving average is $0.07 and its 200 day simple moving average is $0.06.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.